140 related articles for article (PubMed ID: 37407397)
1. Canadian Newspapers Support Mifepristone Medication Abortion to Improve Fulfillment of the AAAQ Right to Health Framework (2015-2019).
Kendall T; Sriram P; Parmar A; Norman WV
Womens Health Issues; 2023; 33(6):592-599. PubMed ID: 37407397
[TBL] [Abstract][Full Text] [Related]
2. Exploring Canadian women's knowledge of and interest in mifepristone: results from a national qualitative study with abortion patients.
Vogel KI; LaRoche KJ; El-Haddad J; Chaumont A; Foster AM
Contraception; 2016 Aug; 94(2):137-42. PubMed ID: 27125893
[TBL] [Abstract][Full Text] [Related]
3. Integrating mifepristone into primary care in Canada's capital: A multi-methods exploration of the Medical Abortion Access Project.
LaRoche KJ; Wylie A; Persaud M; Foster AM
Contraception; 2022 May; 109():37-42. PubMed ID: 35031301
[TBL] [Abstract][Full Text] [Related]
4. "It gives you autonomy over your own choices": A qualitative study of Canadian abortion patients' experiences with mifepristone and misoprostol.
LaRoche KJ; Foster AM
Contraception; 2020 Jul; 102(1):61-65. PubMed ID: 32304768
[TBL] [Abstract][Full Text] [Related]
5. Trends in medication abortion provision before and after the introduction of mifepristone: A study of the National Abortion Federation's Canadian member services.
Yalahow A; Doctoroff J; Mark A; Foster AM
Contraception; 2020 Aug; 102(2):119-121. PubMed ID: 32325077
[TBL] [Abstract][Full Text] [Related]
6. Advancing Reproductive Health through Policy-Engaged Research in Abortion Care.
Munro SB; Dunn S; Guilbert ER; Norman WV
Semin Reprod Med; 2022 Nov; 40(5-06):268-276. PubMed ID: 36746159
[TBL] [Abstract][Full Text] [Related]
7. Pharmacist direct dispensing of mifepristone for medication abortion in Canada: a survey of community pharmacists.
Zusman EZ; Munro S; Norman WV; Soon JA
BMJ Open; 2022 Oct; 12(10):e063370. PubMed ID: 36207038
[TBL] [Abstract][Full Text] [Related]
8. "I'll just deal with this on my own": a qualitative exploration of experiences with self-managed abortion in the United States.
Raifman S; Ralph L; Biggs MA; Grossman D
Reprod Health; 2021 May; 18(1):91. PubMed ID: 33947413
[TBL] [Abstract][Full Text] [Related]
9. Provision of first-trimester medication abortion in 2019: Results from the Canadian abortion provider survey.
Ennis M; Renner R; Guilbert E; Norman WV; Pymar H; Kean L; Carson A; Martin-Misener R; Dunn S
Contraception; 2022 Sep; 113():19-25. PubMed ID: 35351448
[TBL] [Abstract][Full Text] [Related]
10. Assessing abortion coverage in nurse practitioner programs in Canada: a national survey of program directors.
Sheinfeld L; Arnott G; El-Haddad J; Foster AM
Contraception; 2016 Nov; 94(5):483-488. PubMed ID: 27374736
[TBL] [Abstract][Full Text] [Related]
11. A cross-sectional analysis of mifepristone, misoprostol, and combination mifepristone-misoprostol package inserts obtained in 20 countries.
Frye LJ; Kilfedder C; Blum J; Winikoff B
Contraception; 2020 May; 101(5):315-320. PubMed ID: 32032639
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Outcomes before and after Ohio's Law Mandating Use of the FDA-Approved Protocol for Medication Abortion: A Retrospective Cohort Study.
Upadhyay UD; Johns NE; Combellick SL; Kohn JE; Keder LM; Roberts SC
PLoS Med; 2016 Aug; 13(8):e1002110. PubMed ID: 27575488
[TBL] [Abstract][Full Text] [Related]
13. Systematic Review of the Effectiveness, Safety, and Acceptability of Mifepristone and Misoprostol for Medical Abortion in Low- and Middle-Income Countries.
Ferguson I; Scott H
J Obstet Gynaecol Can; 2020 Dec; 42(12):1532-1542.e2. PubMed ID: 32912726
[TBL] [Abstract][Full Text] [Related]
14. Medical termination for pregnancy in early first trimester (≤ 63 days) using combination of mifepristone and misoprostol or misoprostol alone: a systematic review.
Abubeker FA; Lavelanet A; Rodriguez MI; Kim C
BMC Womens Health; 2020 Jul; 20(1):142. PubMed ID: 32635921
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of misoprostol and cervagem in combination with a reduced dose of mifepristone for induction of abortion.
Baird DT; Sukcharoen N; Thong KJ
Hum Reprod; 1995 Jun; 10(6):1521-7. PubMed ID: 7593528
[TBL] [Abstract][Full Text] [Related]
16. Outcomes During Early Implementation of Mifepristone-Buccal Misoprostol Abortions up to 63 Days of Gestation in a Canadian Clinical Setting.
Warden S; Genkin I; Hum S; Dunn S
J Obstet Gynaecol Can; 2019 May; 41(5):647-652. PubMed ID: 31007171
[TBL] [Abstract][Full Text] [Related]
17. Availability of medical abortion medicines in eight countries: a descriptive analysis of key findings and opportunities.
Grossman A; Prata N; Williams N; Ganatra B; Lavelanet A; Läser L; Asmani C; Elamin H; Ouedraogo L; Rahman MM; Conneh-Duworko MJ; Tehoungue BZ; Chanza H; Phiri H; Bhattarai B; Dhakal NP; Ojo OA; Afolabi K; Kabuteni TJ; Hailu BG; Moses F; Dlamini-Nqeketo S; Zulu T; Rehnström Loi U
Reprod Health; 2023 Apr; 20(Suppl 1):58. PubMed ID: 37041543
[TBL] [Abstract][Full Text] [Related]
18. First trimester medication abortion practice in the United States and Canada.
Jones HE; O'Connell White K; Norman WV; Guilbert E; Lichtenberg ES; Paul M
PLoS One; 2017; 12(10):e0186487. PubMed ID: 29023594
[TBL] [Abstract][Full Text] [Related]
19. Mailing abortion pills does not delay care: A cohort study comparing mailed to in-person dispensing of abortion medications in the United States.
Koenig LR; Raymond EG; Gold M; Boraas CM; Kaneshiro B; Winikoff B; Coplon L; Upadhyay UD
Contraception; 2023 May; 121():109962. PubMed ID: 36736715
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days.
Gatter M; Cleland K; Nucatola DL
Contraception; 2015 Apr; 91(4):269-73. PubMed ID: 25592080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
